Scpharmaceuticals Stock Buy Hold or Sell Recommendation
| SCPH Stock | USD 5.18 0.08 1.52% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Scpharmaceuticals is 'Strong Sell'. The recommendation algorithm takes into account all of Scpharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site.
Check out Scpharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide. In addition, we conduct extensive research on individual companies such as Scpharmaceuticals and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Scpharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
Scpharmaceuticals |
Execute Scpharmaceuticals Buy or Sell Advice
The Scpharmaceuticals recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Scpharmaceuticals. Macroaxis does not own or have any residual interests in Scpharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Scpharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | OK | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Scpharmaceuticals Trading Alerts and Improvement Suggestions
| Scpharmaceuticals had very high historical volatility over the last 90 days | |
| Scpharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 13.59 M. Net Loss for the year was (54.81 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Scpharmaceuticals currently holds about 55.85 M in cash with (59.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.04. | |
| Scpharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Roughly 57.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Investors in scPharmaceuticals have unfortunately lost 23 percent over the last year |
Scpharmaceuticals Returns Distribution Density
The distribution of Scpharmaceuticals' historical returns is an attempt to chart the uncertainty of Scpharmaceuticals' future price movements. The chart of the probability distribution of Scpharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Scpharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Scpharmaceuticals returns is essential to provide solid investment advice for Scpharmaceuticals.
| Mean Return | 0.48 | Value At Risk | -4.92 | Potential Upside | 7.40 | Standard Deviation | 4.20 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Scpharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Scpharmaceuticals Stock Institutional Investors
| Shares | State Street Corp | 2024-06-30 | 648.3 K | Geode Capital Management, Llc | 2024-06-30 | 581.8 K | Rice Hall James & Associates, Llc | 2024-06-30 | 497.2 K | Stonepine Capital Management Llc | 2024-06-30 | 421.7 K | Walleye Trading Advisors, Llc | 2024-06-30 | 374.4 K | Bank Of Montreal | 2024-06-30 | 351.8 K | Bmo Capital Markets Corp. | 2024-06-30 | 351.8 K | Northern Trust Corp | 2024-06-30 | 247.9 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 221.3 K | Orbimed Advisors, Llc | 2024-06-30 | 5.6 M | Rubric Capital Management Lp | 2024-06-30 | 3.5 M |
Scpharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (16.9M) | (805K) | 2.4M | (3.2M) | (24.4M) | (23.2M) | |
| Net Borrowings | (62K) | 9.6M | (2.5M) | 29.8M | 34.3M | 36.0M | |
| Free Cash Flow | (30.4M) | (27.7M) | (27.2M) | (34.6M) | (59.3M) | (56.3M) | |
| Depreciation | 364K | 399K | 438K | 468K | 626K | 342.6K | |
| Other Non Cash Items | 385K | 639K | 678K | (695K) | (10.1M) | (9.6M) | |
| Net Income | (33.0M) | (32.2M) | (28.0M) | (36.8M) | (54.8M) | (52.1M) | |
| End Period Cash Flow | 72.8M | 72.0M | 74.5M | 71.2M | 46.8M | 71.7M | |
| Change To Netincome | 1.8M | 2.7M | 2.9M | 3.7M | 4.3M | 3.0M |
Scpharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Scpharmaceuticals or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Scpharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Scpharmaceuticals stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.18 | |
β | Beta against Dow Jones | 2.55 | |
σ | Overall volatility | 4.26 | |
Ir | Information ratio | 0.09 |
Scpharmaceuticals Volatility Alert
Scpharmaceuticals shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Scpharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Scpharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Scpharmaceuticals Fundamentals Vs Peers
Comparing Scpharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Scpharmaceuticals' direct or indirect competition across all of the common fundamentals between Scpharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Scpharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Scpharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Scpharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Scpharmaceuticals to competition |
| Fundamentals | Scpharmaceuticals | Peer Average |
| Return On Equity | -1.67 | -0.31 |
| Return On Asset | -0.42 | -0.14 |
| Profit Margin | (2.52) % | (1.27) % |
| Operating Margin | (1.79) % | (5.51) % |
| Current Valuation | 262.01 M | 16.62 B |
| Shares Outstanding | 50.03 M | 571.82 M |
| Shares Owned By Insiders | 8.45 % | 10.09 % |
| Shares Owned By Institutions | 56.88 % | 39.21 % |
| Number Of Shares Shorted | 5 M | 4.71 M |
| Price To Book | 28.02 X | 9.51 X |
| Price To Sales | 10.78 X | 11.42 X |
| Revenue | 13.59 M | 9.43 B |
| EBITDA | (54.77 M) | 3.9 B |
| Net Income | (54.81 M) | 570.98 M |
| Cash And Equivalents | 55.85 M | 2.7 B |
| Cash Per Share | 2.04 X | 5.01 X |
| Total Debt | 40.27 M | 5.32 B |
| Debt To Equity | 0.32 % | 48.70 % |
| Current Ratio | 3.72 X | 2.16 X |
| Book Value Per Share | 0.26 X | 1.93 K |
| Cash Flow From Operations | (59.24 M) | 971.22 M |
| Short Ratio | 15.11 X | 4.00 X |
| Earnings Per Share | (1.56) X | 3.12 X |
| Target Price | 19.17 | |
| Number Of Employees | 135 | 18.84 K |
| Beta | 0.13 | -0.15 |
| Market Capitalization | 259.15 M | 19.03 B |
| Total Asset | 94.48 M | 29.47 B |
| Retained Earnings | (281.35 M) | 9.33 B |
| Working Capital | 79.8 M | 1.48 B |
| Net Asset | 94.48 M |
Note: Acquisition by Rachael Nokes of 85750 shares of Scpharmaceuticals subject to Rule 16b-3 [view details]
Scpharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Scpharmaceuticals . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Scpharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Scpharmaceuticals? Buying financial instruments such as Scpharmaceuticals Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Scpharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aggressive Funds Thematic Idea Now
Aggressive Funds
Funds or Etfs that attempt to achieve high capital gains by investing in companies with high growth potential and above average risk. The Aggressive Funds theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in Scpharmaceuticals Stock
When determining whether Scpharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Scpharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Scpharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Scpharmaceuticals Stock:Check out Scpharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scpharmaceuticals. If investors know Scpharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scpharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.56) | Revenue Per Share 0.619 | Quarterly Revenue Growth 3.917 | Return On Assets (0.42) | Return On Equity (1.67) |
The market value of Scpharmaceuticals is measured differently than its book value, which is the value of Scpharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Scpharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Scpharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scpharmaceuticals' market value can be influenced by many factors that don't directly affect Scpharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Scpharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Scpharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scpharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.